NEW YORK – Syapse announced a collaboration with Pfizer to collect real-world data on molecular testing patterns and therapy choices made by physicians for cancer patients within the healthcare system.
Syapse said it will work with Pfizer and its network of health system partners to generate real-world evidence that can inform the delivery of precision oncology approaches and advance research.
"Pfizer is committed to using real-world evidence to improve cancer care and decision-making by healthcare providers," Chris Boshoff, chief development officer within the drugmaker's global oncology product development division, said in a statement. "We look forward to working with Syapse and its network of health system partners to better understand the treatment journeys of people living with cancer and develop evidence-based insights that can help improve outcomes."
"To realize the potential of precision medicine, all of the stakeholders in the healthcare ecosystem need to work together," Syapse CEO Ken Tarkoff added in a statement.
This is third real-world data collaboration Syapse has announced with a biopharma partner. Syapse is working with Roche to develop software and analytics solutions that can aid healthcare providers practice precision medicine at scale. Amgen and Syapse are using observational research analytics to identify patients within Syapse's Learning Health Network who may be eligible for Amgen-sponsored clinical trials, so that the drugmaker can bring those trials to more community health system sites.